While undermining pandemic preparedness efforts, the Department of Health and Human Services’ announcement that it would “wind down” messenger RNA vaccine projects related to influenza and COVID-19 wi
BridgeBio Pharma stunned Wall Street in April as it reported Attruby (acoramidis) sales that were triple consensus estimates in the first full quarter of its launch. Clearly, investors were hoping for
Drug makers are enthusiastic about using direct-to-consumer sales as a way to lower drug prices for patients in the US and respond to President Trump’s “most-favored nation” (MFN) drug price proposal,
Drug makers are enthusiastic and continue to discuss ways to implement direct-to-consumer sales to lower US prices, Pfizer CEO Albert Bourla said, but questions about most favored nation pricing str